Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of DR30206 plus standard therapy in advanced non-small cell lung cancer
CTR20262489Phase 2Active
- Sponsor
- Zhejiang Daer Biotechnology
- Start
- Jul 2026
- Modality
- Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of DR30206 in non-small cell lung cancer (NSCLC), sponsored by Zhejiang Daer Biotechnology. Started Jul 2026; status: active.
02
Drugs
DR30206
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20262489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262489.